Novo Nordisk’s Teen Pill Trial Delivers a Rebound, But the Headwinds Are Piling Up

Novo Nordisk shares jump on positive Phase 3 data for oral semaglutide in teens, but the stock remains 50% below its high amid pricing pressure and competition.

Novo Nordisk’s shares surged more than six percent on Friday, snapping a brutal stretch that has left the stock down roughly 22 percent year-to-date. The catalyst: positive Phase 3 data from the PIONEER TEENS study, which tested oral semaglutide in adolescents with type 2 diabetes. The Danish drugmaker’s ADRs closed at €34.95 on Xetra, a rare bright spot in what has been a punishing 12 months.

The trial enrolled 132 patients aged 10 to 17 and showed that oral semaglutide cut HbA1c levels by 0.83 percentage points versus placebo after 26 weeks. The safety profile mirrored that seen in adults. Novo Nordisk now plans to file for pediatric label expansions with the FDA and EMA in the second half of 2026. If approved, the pill would become the first oral GLP-1 therapy available for this age group.

But the rally masks deeper structural problems. The stock remains nearly 50 percent below its 52-week high of €70.13, and the relative strength index of under 18 signals extreme oversold conditions — technically, the rebound was overdue.

A Medicare Workaround and a Failed Payer Deal

On the commercial front, Novo Nordisk confirmed on April 23 that it will participate in the so-called “Medicare GLP-1 Bridge” program starting July 1, 2026. Eligible Medicare Part D beneficiaries will get Wegovy — both the injectable and the new pill — for a $50 monthly copay. The program is a stopgap after the original CMS-BALANCE initiative collapsed. Major insurers like CVS Health and UnitedHealth Group refused to join, citing structural objections, and the required 80 percent enrollment threshold was never met. The bridge will run through the end of 2027.

Meanwhile, Novo Nordisk is preparing to launch oral Ozempic in the US during the second quarter of 2026, targeting type 2 diabetes patients who prefer a non-invasive option. The company hopes to leverage the strong brand recognition of the injectable version, but management has warned that 2026 revenue and operating profit could decline due to pricing pressure and political uncertainty surrounding GLP-1 drugs in the US.

Generics, Amazon, and Eli Lilly Close In

The competitive landscape is tightening. In India, patent protection for Wegovy and Ozempic has expired, and roughly 40 generic manufacturers now offer the active ingredients for an estimated $36 per month — less than half the original price. Novo Nordisk has responded with price adjustments but publicly downplays the threat.

In the US, Amazon is pushing into the GLP-1 market, and Eli Lilly is rolling out its own oral obesity therapies. Despite the noise, some institutional investors are betting on a turnaround: M&T Bank Corp recently boosted its Novo Nordisk position by more than 300 percent, to roughly 317,000 shares.

Buybacks, Capacity, and a Split Analyst Consensus

Novo Nordisk remains active on the capital returns front. A 15 billion Danish krone buyback program launched in February 2026, and nearly 10 million B-shares had been repurchased by early April. The company is also investing heavily in production capacity to meet expected demand for both injectable and oral semaglutide in the US and Europe.

Analyst views are sharply divided. Sanford Bernstein upgraded the stock with a $175 price target, while the TipRanks consensus sits at “Hold” with an average target of around $65.56. The current price-to-earnings ratio of roughly 11.8 is well below the historical median — a sign of deep uncertainty about future earnings power.

For now, the PIONEER TEENS data has given Novo Nordisk a much-needed lift. Whether the pediatric filings proceed as planned in the second half of 2026 will be the next real test of market confidence.